The association between nonalcoholic fatty liver disease and metabolic comorbidities
- Read more about The association between nonalcoholic fatty liver disease and metabolic comorbidities
Qian Zhao, Xinyue Tang, Jiansheng Wu – 18 December 2017
Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model
Miguel Á. Manzanares, Deanna J.W. Campbell, Gabrielle T. Maldonado, Alphonse E. Sirica – 18 December 2017 – Periostin and mesothelin have each been suggested to be predictors of poor survival for patients with intrahepatic cholangiocarcinoma, although the clinical prognostic value of both of these biomarkers remains uncertain. The aim of the current study was to investigate these biomarkers for their potential to act as tumor progression factors when assessed in orthotopic tumor and three‐dimensional culture models of rat cholangiocarcinoma progression.
Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis
Ahmad Hassan Ali, James H. Tabibian, Navine Nasser‐Ghodsi, Ryan J. Lennon, Thomas DeLeon, Mitesh J. Borad, Moira Hilscher, Marina G. Silveira, Elizabeth J. Carey, Keith D. Lindor – 15 December 2017 – Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma (CCA) and gallbladder carcinoma (GBCa). Surveillance for GBCa is recommended, but the clinical utility of surveillance for other hepatobiliary cancers (HBCa) in PSC, namely CCA and hepatocellular carcinoma (HCC), remains unclear.
Significance of measured intraoperative portal vein flows after thrombendvenectomy in deceased donor liver transplantations with portal vein thrombosis
Mikel Gastaca, Mikel Prieto, Ibone Palomares, Andrés Valdivieso – 14 December 2017
Hepatology mentorship: A bold idea: Data from the emerging liver scholars program
Christina C. Lindenmeyer, Elizabeth May – 12 December 2017
Comment on Hakvoort et al.
Natalia Qvartskhava, Cheng Jun Jin, Boris Görg, Dieter Häussinger – 12 December 2017
Reply
Theodorus B.M. Hakvoort, Wouter H. Lamers – 12 December 2017
Regression of HCV cirrhosis: Time will tell
Guadalupe Garcia‐Tsao – 9 December 2017
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis
Zobair M. Younossi, Rohit Loomba, Quentin M. Anstee, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Zachary D. Goodman, Naga P. Chalasani, Kris V.
Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study
Jagpreet Chhatwal, Sumeyye Samur, Emily D. Bethea, Turgay Ayer, Fasiha Kanwal, Chin Hur, Mark S. Roberts, Norah Terrault, Raymond T. Chung – 9 December 2017 – Under current guidelines, hepatitis C virus (HCV)‐positive livers are not transplanted into HCV‐negative recipients because of adverse posttransplant outcomes associated with allograft HCV infection.